Dr. John Cush RheumNow
1 year 2 months ago
Swedish Medical Birth Register study of pregnancy in systemic sclerosis (SSc) shows increased risk of preeclampsia (RR 3.8; 1.8-7.8), preterm birth (3.3; 1.8-6.1), & caesareans (2.5; 1.8-3.5) esp w/ 1st pregnancy -- but not incr. maternal or neonatal death, nor stillbirth https://t.co/SNSK5947zO
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
The Centers for Medicare & Medicaid Services (CMS) announced a new experimental model late last week to streamline some prior authorizations under the traditional Medicare program, but some politicians and experts are concerned that it could result in more delays in care.
Dr. John Cush RheumNow
1 year 2 months ago
Reducing Progression of Psoriasis to Psoriatic Arthritis
Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to psoriatic arthritis (PsA), a retrospective study indicated.
https://t.co/xOtA2Hrgue https://t.co/S522IYnFgz
Dr. John Cush RheumNow
1 year 2 months ago
Diffuse idiopathic skeletal hyperostosis (DISH)is a structural cause of dysphagia due to anterior cervical osteophytes. Retrospective study 208 dysphagia pts w/ head/neck CT. DISH was Dx in 39%; predicted by low serum albumin, COPD, & chronic pain https://t.co/zrn4dnCtLc https://t.co/svE6khmUEm
Dr. John Cush RheumNow
1 year 2 months ago
EUSTAR Study of 893 SSc-ILD pts - 94 (10.5%) died (mean F/U 39 mos). Predictors of mortality: FVC deterioration >10% w/in 12 mos (HR 3.81) & >10% FVC decline or mRSS worsening (HR 2.82); but not changes in DLCO, mRSS or digital ulcer burden alone. https://t.co/28wSQc1dUS https://t.co/dourQ6WGDq
Dr. John Cush RheumNow
1 year 2 months ago
Early DMARD Initiation Benefits in Psoriatic Arthritis
Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late https://t.co/EdbnpBmnPe
Dr. John Cush RheumNow
1 year 2 months ago
Despite 2024 HHS proposal to reschedule CANNABIS to Schedule III, it remains Schedule I -having "no accepted medical use" and "high abuse potential".There's lots of use (legal in 24 states, DC, decriminalized in 7 states), but no evidence, research or guidelines. https://t.co/KumpvMHdhC
A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA). The observed incidences of malignant neoplasms were consistent with the US general population.
Dr. John Cush RheumNow
1 year 2 months ago
Immunomodulators in the Treatment of Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease driven by autoimmune mechanisms, characterized by elevated serum aminotransferases, hypergammaglobulinemia, and interface hepatitis on https://t.co/KgzjNvrZ7v
Dr. John Cush RheumNow
1 year 2 months ago
Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositis, antisynthetase syndrome & overlap myositis. Full read overview of inflammatory myositis & new treatments from Joint Bone & Spine https://t.co/X46sptp1Ax https://t.co/QqyMv6fkVS
Dr. John Cush RheumNow
1 year 2 months ago
1 yr study of falls studied in 100 RA & 80 PsA pts. 33% of RA & 46% of PsA reported falls, w/ a higher frequency in PsA Pts (p=0.02). Falls associated w/ disease duration and HAQ score. As falls are assoc w/ high morbidity & mortality risk, pts should be questioned about FALLS https://t.co/tP7zmGCZcw
Dr. John Cush RheumNow
1 year 2 months ago
Referral of 304 suspected autoinflammatory Dz (SAID) to a UK national centre for primarily adult SAID in 2022, 121 (39.5%) were diagnosed with SAID, w/ half of these having monogenic Dz. Median Dx delay was 2 to 6 yrs, worse in late-onset SAID. https://t.co/x8VOFyjuVA https://t.co/3R2HdYUlSg
